Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39
Why Amylyx Pharmaceuticals Stock Is Up 6.8% And What's Next
Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results
Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified?
Amylyx Pharmaceuticals Inc (AMLX) Q3 2026 Earnings Call Highlights: $768 Million Cash Position ...
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
Amylyx (AMLX) Q3 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Amylyx Pharma Q3 EPS $(0.38), Inline
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting
Amylyx Pharma Q2 2026 Earnings Call Transcript
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.